Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester.
Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester.
复制标题
DOI：
10.3390/v14020307
复制
发表时间：
2022-02-02
期刊：
影响因子：
--
通讯作者：
Malita D
中科院分区：
文献类型：
--
作者：
Citu IM;Citu C;Gorun F;Sas I;Tomescu L;Neamtu R;Motoc A;Gorun OM;Burlea B;Bratosin F;Malita D
在全球范围内，COVID-19疫苗目前正用于预防传播，并减少与SARS-CoV-2感染相关的发病率和死亡率。目前的研究表明，BNT 162 b2和Ad26.COV2.S等疫苗具有高度免疫原性，对大多数已知的病毒变体具有较高的短期有效性。临床试验在一般人群中显示出令人满意的结果，但由于不愿对孕妇进行检测和接种，这类人群在接种COVID-19疫苗后的安全性、有效性和免疫原性方面几乎没有证据。随着COVID-19在全球范围内的发病率居高不下，以及出现新的传染性SARS-CoV-2突变的可能性，有关怀孕患者的疫苗接种有效性和抗体动态的数据对于确定是否需要特殊护理或进一步加强剂量至关重要。开发了一项观察性研究，以评估使用BNT 162 b2和Ad26.COV2.S接受完整COVID-19疫苗接种计划的孕妇，并确定母亲及其新生儿的妊娠相关结局，以及确定疫苗接种后的不良事件和疫苗在四个月内的免疫原性。比较接种疫苗与未接种疫苗的孕妇，未发现妊娠和新生儿特征异常。COVID-19血清反应阳性的孕妇的棘突抗体滴度明显高于具有类似特征的血清反应阴性患者，尽管她们在接种疫苗后更容易出现发热和淋巴结病。同一组孕妇在4个月期间与病例匹配的非孕妇相比，抗体滴度无统计学显著差异。BNT 162 b2和Ad26.COV2.S疫苗在妊娠晚期接种是安全的，其安全性、有效性和免疫原性与一般人群相似。
Globally, COVID-19 vaccines are currently being used to prevent transmission and to reduce morbidity and death associated with SARS-CoV-2 infection. Current research reveals that vaccines such as BNT162b2 and Ad26.COV2.S are highly immunogenic and have high short-term effectiveness for most of the known viral variants. Clinical trials showed satisfying results in the general population, but the reluctance in testing and vaccinating pregnant women left this category with little evidence regarding the safety, efficacy, and immunogenicity following COVID-19 vaccination. With the worldwide incidence of COVID-19 remaining high and the possibility of new transmissible SARS-CoV-2 mutations, data on vaccination effectiveness and antibody dynamics in pregnant patients are critical for determining the need for special care or further booster doses. An observational study was developed to evaluate pregnant women receiving the complete COVID-19 vaccination scheme using the BNT162b2 and Ad26.COV2.S, and determine pregnancy-related outcomes in the mothers and their newborns, as well as determining adverse events after vaccination and immunogenicity of vaccines during four months. There were no abnormal findings in pregnancy and newborn characteristics comparing vaccinated versus unvaccinated pregnant women. COVID-19 seropositive pregnant women had significantly higher spike antibody titers than seronegative patients with similar characteristics, although they were more likely to develop fever and lymphadenopathy following vaccination. The same group of pregnant women showed no statistically significant differences in antibody titers during a 4-month period when compared with case-matched non-pregnant women. The BNT162b2 and Ad26.COV2.S vaccines are safe to administer during the third trimester of pregnancy, while their safety, efficacy, and immunogenicity remain similar to those of the general population.
登录
查看更多内容
影响因子：
9.4
作者：
Higgins V;Fabros A;Kulasingam V
通讯作者：
Kulasingam V
影响因子：
3.2
作者：
Garg I;Shekhar R;Sheikh AB;Pal S
通讯作者：
Pal S
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
7.8
作者：
Principi N;Esposito S
通讯作者：
Esposito S
影响因子：
13.8
作者：
Kachikis A;Englund JA;Singleton M;Covelli I;Drake AL;Eckert LO
通讯作者：
Eckert LO